-
61.
公开(公告)号:EP3880223A1
公开(公告)日:2021-09-22
申请号:EP19885238.6
申请日:2019-11-13
申请人: Leahy Orchards Inc.
发明人: LEVY, Emile , LEAHY, Michael
IPC分类号: A61K36/73 , A61K31/353 , A61P1/16 , A61P39/06 , C07D311/62
-
公开(公告)号:EP3312169B1
公开(公告)日:2021-09-15
申请号:EP17198245.7
申请日:2013-07-16
发明人: HITCHCOCK, Stephen , MONENSCHEIN, Holger , REICHARD, Holly , SUN, Huikai , KIKUCHI, Shota , MACKLIN, Todd , HOPKINS, Maria
IPC分类号: A61K31/5386 , A61P1/04 , A61P25/06 , C07D451/12 , C07D498/08 , A61K31/19 , C07D221/22 , C07D453/02 , C07D471/04 , C07D471/08 , C07D519/00 , A61P43/00 , A61P39/00 , A61P29/00
-
-
64.
公开(公告)号:EP3848025A1
公开(公告)日:2021-07-14
申请号:EP20216079.2
申请日:2020-12-21
IPC分类号: A61K31/198 , A61K31/194 , A61K31/704 , A61P9/00 , A61P39/00 , A61P43/00
摘要: Composition for use in the prevention and/or in the treatment of cardiotoxicity induced by at least one chemotherapeutic agent in a subject undergoing chemotherapy, the composition comprising an active agent, said active agent containing the amino acids leucine, isoleucine, valine, threonine, lysine and citric acid, succinic acid, malic acid. Said chemotherapeutic agent may be selected in the group consisting of anthracyclines, HER2/ErbB2 inhibitors, tyrosine-kinase inhibitors, vascular endothelial growth factor inhibitors, immune checkpoint inhibitors.
-
公开(公告)号:EP3846832A1
公开(公告)日:2021-07-14
申请号:EP19770231.9
申请日:2019-09-04
申请人: Innophos, Inc.
发明人: RANA, Jatinder , MITCHELL, Kylie
-
公开(公告)号:EP3843557A1
公开(公告)日:2021-07-07
申请号:EP19746305.2
申请日:2019-07-12
申请人: Innophos, Inc.
发明人: RANA, Jatinder , MITCHELL, Kylie
IPC分类号: A23L33/105 , A61K36/22 , A61P39/06
-
公开(公告)号:EP2922816B1
公开(公告)日:2021-06-23
申请号:EP13856781.3
申请日:2013-11-25
IPC分类号: C07C229/16 , C07C229/26 , C07C227/14 , A61P39/04
-
公开(公告)号:EP3654984B1
公开(公告)日:2021-06-16
申请号:EP18756506.4
申请日:2018-07-19
IPC分类号: A61K39/395 , A61P17/00 , A61K31/517 , A61P39/00 , A61K31/5377 , A61K9/00
-
公开(公告)号:EP3052194B1
公开(公告)日:2021-06-16
申请号:EP14792846.9
申请日:2014-09-29
IPC分类号: A61K31/519 , A61P43/00 , A61K9/00 , A61K31/506 , A61K31/48 , A61K31/435 , A61K31/428 , A61K31/404 , A61K31/38 , A61K9/08 , A61K31/4045 , A61P1/00 , A61P39/00 , A61P39/02
-
70.
公开(公告)号:EP3827819A1
公开(公告)日:2021-06-02
申请号:EP21153063.9
申请日:2016-09-30
申请人: EPITECH GROUP S.p.A.
IPC分类号: A61K31/164 , A61K31/728 , A61P19/02 , A61P19/04 , A61P17/10 , A61P17/02 , A61P27/02 , A61P35/00 , A61P37/00 , A61P39/00
摘要: The present invention concerns Adelmidrol for use in the treatment of diseases characterized by insufficient specific agonism of the PPAR-gamma receptor in humans or animals selected from diseases characterized by an abnormal fibrosis of the connective tissue of the lung.
-
-
-
-
-
-
-
-
-